CraniUS Gains $1 Million in Funding to Advance its Neurotechnology Platform

CraniUS has been awarded a competitive $1 million grant from the state of Maryland to advance its skull-embedded neurotechnology research.

The grant is part of Gov. Wes Moore’s Build Our Future Innovation Infrastructure Pilot Program and represents the first funding awarded as part of the initiative. The money will help CraniUS expand its research capabilities, accelerate product development into human studies, and enhance its contributions to Maryland’s innovation ecosystem.

Moore last year officially launched the Build Our Future program—a $9 million initiative designed to support transformative projects across Maryland’s strategic industry sectors. The program provides matching grants of up to $2 million to projects that demonstrate a substantial impact on growth and innovation within the state.

CraniUS’s work in skull-embedded neurotechnology aims to revolutionize treatments for neurological disorders by pioneering a new frontier: the brain-medicine interface (BMI), creating an expansive new platform in neurological medicines that can be delivered safely and directly to the brain to treat multiple diseases. Its patented flagship device, the NeuroPASS, is being specifically developed to bypass the challenges presented by the blood-brain barrier, which has rendered traditional therapeutic treatments of brain disease ineffective.

“We are thrilled and grateful to receive this support from the State of Maryland,” CraniUS CEO Mike Maglin said. “This grant is not just a recognition of our groundbreaking work, but a testament to the state’s commitment to fostering innovation and supporting high-impact projects. With this funding, we are poised to make significant strides in our mission to develop life-changing neurotechnology solutions.”

CraniUS was founded May 2021 in Baltimore, Md., as a byproduct of the emerging neuroplastic and reconstructive surgery field through the vision, insight, and work of Dr. Chad Gordon. CraniUS has raised more than $24 million to date, been issued seven patents, and is currently in the midst of a Series B fundraising round.

CraniUS’s NeuroPASS device is currently in the pre-clinical development stage and is not yet commercially available. It is on the pathway to clinical studies.